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Abstract 
 
Objectives 
 
This pilot study investigated the association of four PET image features and cyclo-
oxygenase-2 (COX-2) expression in patients with oesophageal adenocarcinoma.  The 
prognostic significance of these biomarkers was also assessed. 
 
Methods 
 
Fifty consecutive patients [median age=68 (range 47-84), males=45) with oesophageal 
adenocarcinoma had PET/CT staging between January 2011 and July 2015.  The 
maximum and mean standardised uptake values (SUVmax and SUVmean), metabolic 
tumour volume (MTV) and tumour lesion glycolysis (TLG) were calculated from the 
primary tumour. Their association with COX-2 status was assessed using Mann-Whitney 
U tests. Kaplan-Meier and Cox regression analysis tested their prognostic significance. 
A p-value <0.05 was considered statistically significant. 
 
Results 
 
Thirty-two tumours (64.0%) were COX-2 positive.  There was a significant association 
between SUVmean and COX-2 status (p=0.019).  TLG (hazard ratio (HR) 1.001, 95% 
confidence intervals (CI) 1.000-1.002, p=0.018) was significantly associated with overall 
survival on multivariable analysis. 
 
Conclusions 
 
This study investigated the association between PET image features and COX-2 
expression in oesophageal adenocarcinoma.  The preliminary results signal that a 
combination of TLG (calculated as product of MTV and SUVmean) and COX-2 status may 
be a strong and clinically important prognostic biomarker. Our research group are 
planning a prospective, multi-centre study to validate these findings. 
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Advances in knowledge 
 
1. Mean standardised uptake value (SUVmean) on PET imaging is associated with COX-
2 expression in oesophageal adenocarcinoma. 
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Introduction 
 
The prognosis of oesophageal cancer is poor and adenocarcinoma is the most 
common histological cell type in developed countries. [1] The development of 
oesophageal adenocarcinoma has been linked with prolonged mucosal 
inflammation causing progression through the metaplastic to dysplastic to 
adenocarcinoma sequence. [2] 
 
Cyclo-oxygenase-2 (COX-2) is involved in promoting angiogenesis and is an 
enzyme that is activated in response to extra-cellular stimuli such as pro-
inflammatory cytokines. [3] It is over-expressed in epithelial solid cancers 
associated with inflammation. Non-steroidal anti-inflammatory drugs (NSAIDS) 
may reduce the risk of cancer in the gastrointestinal (GI) tract and aspirin has 
become the focus of preventative clinical trials. [4] Importantly, COX-2 has been 
shown to have prognostic significance. [5] 
 
Positron emission tomography (PET) combined with computed tomography 
(CT) using 18-F fluorodeoxyglucose (FDG) is now routinely used in the 
oesophageal cancer staging pathway. The focus of many PET research studies 
in oesophageal cancer is the identification of prognostic imaging biomarkers. 
Our research group have found that PET image features, maximum and mean 
standardised uptake value (SUVmax and SUVmean), metabolic tumour volume 
(MTV) and tumour lesion glycolysis (TLG) have prognostic significance [6], with 
similar results confirmed in other studies. [7,8] 
 
Prognostic biomarker studies that correlate immunohistochemical tumour 
marker expression with imaging biomarkers are currently lacking in 
oesophageal cancer research, however an association between the SUVmax 
and COX-2 has been found in lung adenocarcinoma. [9] The discovery of 
combined prognostic radiological and pathological biomarkers may improve 
patient risk stratification and treatment decision making. Improved patient 
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selection for more personalised treatment regimens may ultimately improve the 
currently low survival rates. 
 
Therefore, the primary aim of this pilot study was to obtain preliminary data 
associating PET image features (SUVmax, SUVmean, MTV and TLG) and COX-2 
expression in oesophageal adenocarcinoma. The secondary aim was to assess 
the prognostic significance of these biomarkers. 
 
 
Materials & Methods 
 
Patient Selection 
This retrospective pilot study considered all consecutive patients with biopsy-
proven oesophageal and gastro-oesophageal junction adenocarcinoma in a 
single tertiary centre who had staging PET/CT between January 2011 and July 
2015 (n=71). Patients were radiologically staged using the TNM 7th edition. [10] 
Given that consecutive patients were studied, the patients included in the study 
received a variety of surgical, oncological and palliative treatments. (Table 1)  
Ethical approval was granted to quantify COX-2 expression from archived tissue 
and correlate with routinely performed PET/CT (REC 14/WA/1208). The 
requirement for informed consent was waived. 
 
Patients with insufficient archived tissue from the biopsy sample (n=17) and 
cases in which the primary tumour was non-avid on PET/CT (n=4) were 
excluded. Fifty patients were included in the study. 
 
PET image features 
The standard PET/CT protocol in our centre has previously been published in 
detail [6] and is included in Appendix 1. This identical protocol was used for 
each patient in this study. (Fig. 1) Data preparation was performed by a single 
researcher, a radiology resident with 5 years’ experience of PET research who 
was blinded to COX-2 status.  Primary oesophageal tumour delineation was 
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performed using the Automatic decision Tree-based Learning Algorithm for 
Advanced image Segmentation in positron emission tomography (ATLAAS) tool 
[11], which eliminates inter-observer variation in tumour outline. SUVmax, 
SUVmean, MTV and TLG were automatically calculated from the primary tumour 
only using software developed and validated by our research group. Further 
details are included in Appendix 1. The SUVmax is the value extracted from the 
pixel with the highest uptake value in the ATLAAS-defined region of interest. 
The SUVmean is calculated as the average uptake value across the MTV. TLG is 
calculated as the product of SUVmean and MTV. 
 
COX-2 Preparation 
COX-2 analysis was performed from archived diagnostic biopsy tissue because 
this biomarker is not routinely tested during the staging pathway. The tissue 
was obtained prior to PET/CT and treatment initiation. COX-2 staining was 
performed on the Leica Bond III automated immunostaining platform and 
detection carried out using the Leica Bond Polymer Refine DAB 
system. Primary antibody COX-2 mouse monoclonal (Clone CX-294, (Dako, 
Ely, UK)) was applied. 
 
COX-2 Quantification 
COX-2 expression was quantified by a Consultant Upper GI Histopathologist 
and classified as a categorical variable based on the intensity of staining using 
the following grading: 0, 1+, 2+ and 3+. [12] (Fig. 2) A grading of 0/1+ was 
considered negative and 2+/3+ considered positive.  A pre-constructed control 
tissue microarray (TMA) was added to the slides as a control with standardised 
3+, 2+, 1+ and 0 scoring tumour for COX-2. Internal negative controls within 
non-tumour components of the biopsies were also tested. 
 
Survival Data 
The secondary outcome of the study was overall survival, defined in months 
from the data of diagnosis.  No patient was lost to follow-up, with each patient 
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receiving clinical follow-up 3-monthly in the first year, then 6-monthly thereafter 
for the next 4 years, or until death. 
 
Statistical analysis 
Categorical variables were described as frequency (percent) and continuous 
variables as median (range). Mann-Whitney U tests were used to assess for 
significant differences between PET image features and COX-2. Chi-square 
tests assessed differences between TNM stage and COX-2 status. Kaplan-
Meier analysis with log-rank test evaluated the association of TNM stage and 
COX-2 status with overall survival. Univariable and multivariable Cox regression 
models tested the association of continuous PET image features with overall 
survival. The multivariable model included TNM stage, SUVmax, SUVmean, MTV, 
TLG and COX-2 status. A p-value <0.05 was considered statistically significant.  
Statistical analysis was performed using SPSS v23.0 (IBM, Chicago, USA). 
 
 
Results 
 
Patient Cohort 
 
Baseline characteristics of the patient cohort are detailed in Table 1. The 
median age of patients was 68.0 years (range 47–84). Thirty-two tumours were 
classified as positive COX-2 status (2+=18, 3+=14) and 18 tumours were 
classified as negative COX-2 status (0=4, 1+=14). Most patients (46%) were 
treated palliatively. 
 
PET Image Features 
 
Four PET image features were calculated from the ATLAAS-defined primary 
tumour. The median SUVmax was 13.49 (min 3.56, max 42.05, interquartile 
range (IQR) 11.85). The median SUVmean was 7.16 (min 2.07, max 34.97, IQR 
5.50). The median MTV was 19.09 mL (min 0.66, max 94.76, IQR 20.13). The 
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median TLG was 125.33 (min 11.25, max 1809.08, IQR 234.69). No significant 
difference in MTV or TLG was found between patients treated with radical intent 
compared with those treated palliatively (p=0.376 and p=0.224, respectively). 
 
Association of TNM Stage and PET Image Features with COX-2 Status 
 
SUVmean (U=172.0, mean rank 31.9 vs 21.9, p=0.019) showed a significant 
association with COX-2 status. (Fig. 3)  A higher grade of COX-2 expression 
correlated with a lower SUVmean value. SUVmax, MTV and TLG did not reach 
statistical significance with COX-2 status (p=0.079, p=0.486 and p=0.203, 
respectively).  
 
Prognostic Significance of TNM Stage, PET Image Features and COX-2 Status 
 
MTV (hazard ratio (HR) 1.024, 95% confidence intervals (CI) 1.007-1.041, 
p=0.005) and TLG (HR 1.001, 95% CI 1.000-1.002, p=0.011) were both 
significantly associated with overall survival on univariate analysis. T-stage (X2 
24.998, df 5, p<0.001) and N-stage (X2 12.201, df 3, p=0.007) were significantly 
associated with overall survival. As there were only 10 cases with M1 disease, 
M-stage had borderline prognostic significance (X23.151, df 1, p=0.076). 
SUVmax (p=0.803) and SUVmean (p=0.838) were not associated with overall 
survival. COX-2 status was also not associated with overall survival (X2 0.010, 
df 1, 0.921). (Fig. 4) After 36 months, the negative and positive status groups 
appeared to separate, but this was not statistically significant, possibly a 
reflection on the small sample size. On multivariable analysis, T-stage 
(p=0.008) and TLG (p=0.18) were independently and significantly associated 
with overall survival. (Table 2) 
 
Discussion 
 
This study presents preliminary data regarding COX-2 expression and PET 
image features in oesophageal adenocarcinoma. SUVmean was associated with 
  9 
COX-2 status, with positive COX-2 expression linked to lower FDG-uptake 
values. In addition, MTV on univariable analysis, and T-stage and TLG on 
multivariable analyses were significantly associated with overall survival in this 
patient cohort. 
 
These findings suggest that metabolic activity on FDG-PET may be influenced 
by COX-2 expression. Variation in FDG-uptake is associated with underlying 
pathophysiological features such as angiogenesis, vascularity, perfusion, 
hypoxia and necrosis. [13] Furthermore, COX-2 has a role in angiogenesis and 
subsequently tumour vasculature. This pilot study demonstrated an unexpected 
inverse association between FDG-uptake and COX-2 status. Previous research 
has suggested that COX-2 may be over-expressed in more aggressive tumours 
which tend to be associated with higher FDG-uptake. [14] However, this inverse 
association has been found in other tumour sites including breast. [15] 
 
The cause of this inverse association is not fully understood. CT perfusion 
studies in oesophageal and colorectal cancer have investigated tumour 
vasculature. [16] This dynamic technique quantifies tumour perfusion and can 
predict response to neo-adjuvant treatment.  In oesophageal cancer, increased 
blood flow and reduced mean transit time are associated with tumour 
regression grade.  To date, no in vivo studies have investigated COX-2 
expression and tumour perfusion in oesophageal cancer, but increased COX-2 
may promote angiogenesis, resulting in varied tumour blood flow affecting 
tumour growth and hence reduced metabolic activity. Alternatively, variation in 
angiogenesis may contribute to intra-tumoural necrosis and reduced FDG-
uptake. These hypotheses may explain the inverse relationship identified here 
but the relationship between COX-2 expression and FDG-uptake remains 
controversial. [14] 
 
COX-2 expression is prognostically significant.  In one systematic review and 
meta-analysis in oesophageal adenocarcinoma, COX-2 had the largest survival 
effect (HR 2.47, 95% CI 1.15-3.79) out of 9 tumour markers including human 
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epidermal receptor growth factor 2 (HER-2) and Ki-67. [5] In this current study, 
MTV on univariable and TLG on multivariable analyses were significantly 
associated with overall survival. These results support other published 
research. [7] As expected, disease stage was also significantly associated with 
overall survival. Tumours with larger MTV and higher FDG-uptake are likely to 
indicate more advanced tumours and therefore be associated with poorer 
outcomes. Although COX-2 was not prognostically significant in this patient 
cohort, preliminary data was obtained from 50 consecutive patients only. This 
pilot study is under-powered to detect this difference and a larger cohort may 
have demonstrated statistical significance between COX-2 status groups. In 
addition, treatment regimens did not influence survival differences between 
these groups, with relatively equal proportions of patients receiving radical or 
palliative treatments. 
 
Given the proven link of increased cancer risk with inflammation, the 
association with COX-2 status and FDG-uptake on PET could signal the 
potential for clinically important combined biomarkers. Aspirin has become the 
focus of preventative clinical trials given the link between non-steroidal anti-
inflammatory drug (NSAID) use and inflammation in cancer. [4] COX-2 is 
thought to be over-expressed in areas of inflammation such as segments of 
Barrett’s oesophagus. [2] Our research group is planning a prospective, multi-
centre study to further investigate and validate the association of COX-2 status 
and PET image features in oesophageal adenocarcinoma. Such research 
should follow the key recommendations outlined in the imaging biomarker 
roadmap for cancer studies, which describes the necessary stages in the 
translational pathway of potential image biomarkers from discovery to validation 
and adoption into clinical practice. [17] 
 
This pilot study had several strengths.  All patients underwent PET/CT using an 
identical protocol and scanner.  This sample of patients were treated as part of 
a large, experienced Regional Upper GI cancer MDT, serving a population of 
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over 1.4 million.  All diagnostic biopsies and tumour markers were evaluated by 
a Consultant GI Histopathologist.  No patients were lost to follow-up. 
 
Limitations 
 
This retrospective, single centre pilot study with a small patient cohort has a 
number of limitations which should be addressed in future studies. As for similar 
studies involving biopsy data, it is possible that results are affected by 
differences in tumour marker expression between the sample and the whole 
imaged tumour volume.  Multiple populations of clonal cells are known to exist 
within tumours, therefore independent biopsies sampling different regions of 
malignant tissue may result in varying levels of tumour marker expression.  In 
addition, tumour marker analysis was conducted from archived tissue.  Older 
tissue may degrade affecting its quality and quantity [18] but cases in which 
there was insufficient tissue were excluded from this study. The oldest biopsy in 
our cohort was 4 years old. 
 
Conclusion 
 
This pilot study associated PET image features and COX-2 expression in 
oesophageal adenocarcinoma.  This study provides preliminary evidence that 
SUVmean is associated with COX-2 status and further evidence that MTV and 
TLG are prognostically significant. These findings suggest that further research 
is warranted and will inform a prospective, multi-centre study investigating PET 
image features and COX-2 expression. 
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Tables 
 
Table 1. Baseline Characteristics of the Patient Cohort 
Characteristic Frequency (%) 
M: F Ratio 45 (90.0): 5 (10.0) 
Tumour Location 
Oesophagus 
GOJ 
 
23 (46.0) 
27 (54.0) 
Adenocarcinoma Differentiation 
Well 
Moderate 
Poor 
Gx 
 
2 (4.0) 
16 (32.0) 
19 (38.0) 
13 (26.0) 
Radiological T-stage 
T1 
T2 
T3 
T4a 
T4b 
Tx 
 
2 (4.0) 
3 (6.0) 
34 (68.0) 
7 (14.0) 
2 (4.0) 
2 (4.0) 
Radiological N-stage 
N0 
N1 
N2 
N3 
 
13 (26.0) 
14 (28.0) 
15 (30.0) 
8 (16.0) 
Radiological M-stage 
M0 
M1 
 
40 (80.0) 
10 (20.0) 
Stage Groups 
Stage I 
Stage II 
Stage III 
Stage IV 
 
3 (6.0) 
10 (20.0) 
27 (54.0) 
10 (20.0) 
Treatment 
Palliative 
NACT 
dCRT 
Surgery alone 
NACRT 
 
23 (46.0) 
14 (28.0) 
6 (12.0) 
5 (10.0) 
2 (4.0) 
GOJ Gastro-oesophageal junction, Gx/Tx unable to be assessed, NACT neo-
adjuvant chemotherapy, dCRT definitive chemoradiotherapy, NACRT neo-adjuvant 
chemoradiotherapy  
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Table 2. Results of Multivariable Analysis 
 
    95% CI  
Variable p-value Hazard Ratio df Lower Upper 
T-Stage 0.008  5   
T2 0.487 2.272 1 0.224 23.039 
T3 0.878 0.853 1 0.112 6.506 
T4a 0.705 1.548 1 0.162 14.821 
T4b 0.216 4.861 1 0.398 59.406 
Tx 0.019 25.017 1 1.694 369.534 
TLG 0.018 1.001 1 1.000 1.002 
Tx unable to be assessed, df degrees of freedom, CI confidence intervals, TLG 
Tumour Lesion Glycolysis 
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Figures 
 
 
Figure 1. A selected fused PET/CT image showing a FDG-avid distal oesophageal 
adenocarcinoma. 
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Figure 2. A high magnification image of an adenocarcinoma biopsy sample showing 
high COX-2 expression (brown cells). 
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Figure 3. Box-plot representations of COX-2 status with SUVmean (p=0.019). 
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Figure 4. Cumulative survival of negative and positive COX-2 status groups (X2 
0.010, df 1, p=0.921). 
 
 
